mantle cell lymphoma

[Biomarker Research] Scientists discuss the rationale for the combinational use and summarized the current data on the combinations of BTK inhibitors and venetoclax in patients with chronic lymphocytic leukemia and mantle cell lymphoma.

[Therapeutic Advances in Hematology] Investigators provided an overview for the available management strategies for relapsed mantle cell lymphoma (MCL) and examines the role of CAR T cell in the current and future treatment of MCL.

[Nature Communications] Investigators developed a B cell-activating factor (BAFF) ligand-based CAR and generated BAFF CAR-T cells using a non-viral gene delivery method.

[Leukemia & Lymphoma] Investigators retrospectively analyzed 55 patients who underwent allogeneic stem cell transplantation for mantle cell lymphoma relapsed or refractory after rituximab and high-dose cytarabine within the MANTLE-FIRST project.

[Sutro Biopharma, Inc.] Sutro Biopharma, Inc and BioNova Pharmaceuticals Limited announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate, for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

[Stem Cell Research & Therapy] Investigators highlight the preclinical and clinical efforts made for addressing the drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T cell malignancies.